Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...
Zacks.com on MSN6d
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLACapricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...
Linda Marbán, Ph.D., the Chief Executive Officer of Capricor, emphasized the significance of this milestone, highlighting the potentially transformative impact of deramiocel on individuals grappl ...
Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application (BLA) to the FDA seeking full approval for deramiocel to ...
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback